NOVARTIS
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects
- First Posted Date
- 2006-12-20
- Last Posted Date
- 2008-01-15
- Lead Sponsor
- Novartis
- Target Recruit Count
- 162
- Registration Number
- NCT00413790
- Locations
- 🇺🇸
Investigative Site, Dallas, Texas, United States
LBH589 in Adult Patients With Advanced Solid Tumors or Cutaneous T-cell Lymphoma
Phase 1
Completed
- Conditions
- TumorsCutaneous T-Cell Lymphoma
- Interventions
- Drug: LBH589
- First Posted Date
- 2006-12-19
- Last Posted Date
- 2012-11-27
- Lead Sponsor
- Novartis
- Target Recruit Count
- 14
- Registration Number
- NCT00412997
- Locations
- 🇯🇵
Novartis Investigative Site, Tokyo, Japan
Efficacy/Safety of Valsartan Plus Amlodipine and Amlodipine Alone in Patients With Hypertension
Phase 3
Completed
- Conditions
- Hypertension
- Interventions
- Drug: Valsartan/amlodipine 80/5 mgDrug: Amlodipine 5 mg
- First Posted Date
- 2006-12-19
- Last Posted Date
- 2011-04-29
- Lead Sponsor
- Novartis
- Target Recruit Count
- 698
- Registration Number
- NCT00413049
- Locations
- 🇨🇳
Institute of Hypertension, Ruijin Hospital, Shanghai, China
🇨🇳Zhongshan hospital affiliated Fudan University, Shanghai, China
🇨🇳The sixth people's hospital of Shanghai, Shanghai, China
Study to Compare How the Body Changes the Blood Level of Darifenacin Tablet Form vs. the Modified Release Liquid Form in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy
- First Posted Date
- 2006-12-19
- Last Posted Date
- 2016-04-12
- Lead Sponsor
- Novartis
- Target Recruit Count
- 28
- Registration Number
- NCT00413426
- Locations
- 🇮🇳
Novartis Investigative Site, Mumbai, India
Efficacy and Safety of Telbivudine in Treatment naïve Patients With Hepatitis B e Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB)
Phase 3
Terminated
- Conditions
- Hepatitis B
- Interventions
- Drug: Telbivudine (LdT)Drug: peginterferon alpha-2a
- First Posted Date
- 2006-12-18
- Last Posted Date
- 2011-07-13
- Lead Sponsor
- Novartis
- Target Recruit Count
- 159
- Registration Number
- NCT00412750
- Locations
- 🇺🇸
Novartis, San Francisco, California, United States
A Study to Assess the Efficacy of Inhaled Corticosteroid (ICS) Therapy in Moderate-Severe Bronchial Asthma
Phase 1
Completed
- Conditions
- Bronchial Asthma
- First Posted Date
- 2006-12-14
- Last Posted Date
- 2007-06-22
- Lead Sponsor
- Novartis
- Target Recruit Count
- 26
- Registration Number
- NCT00411567
- Locations
- 🇩🇪
Novartis Investigative Site, Nuernberg, Germany
Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder
Phase 3
Completed
- Conditions
- Major Depressive Disorder (MDD)
- Interventions
- Drug: agomelatineDrug: placebo
- First Posted Date
- 2006-12-13
- Last Posted Date
- 2020-12-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 503
- Registration Number
- NCT00411242
- Locations
- 🇺🇸
Novartis Investigative Site, Milwaukee, Wisconsin, United States
Evaluation of Pharmacokinetic Interaction of Indacaterol With Ketoconazole in Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Healthy
- First Posted Date
- 2006-12-13
- Last Posted Date
- 2007-06-19
- Lead Sponsor
- Novartis
- Target Recruit Count
- 20
- Registration Number
- NCT00410501
- Locations
- 🇮🇳
Novartis, Mumbai, India
Pharmacokinetics and Pharmacodynamics Study of Oral Salmon Calcitonin in Healthy Postmenopausal Women
Phase 1
Completed
- Conditions
- Postmenopausal Osteoporosis
- First Posted Date
- 2006-12-13
- Last Posted Date
- 2006-12-13
- Lead Sponsor
- Novartis
- Target Recruit Count
- 86
- Registration Number
- NCT00411125
Efficacy, Safety and Tolerability of Agomelatine in the Treatment of Major Depressive Disorder
- First Posted Date
- 2006-12-13
- Last Posted Date
- 2020-12-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 508
- Registration Number
- NCT00411099
- Locations
- 🇵🇷
Novartis Investigative Site, Rio Piedras, Puerto Rico
© Copyright 2025. All Rights Reserved by MedPath